n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11)
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Phase 3Active
Key Facts
Indication
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Phase
Phase 3
Status
Active
About ITM Isotopen Technologien München
ITM is a leading radiopharmaceutical biotech company focused on precision oncology, with a core strength in the manufacturing of high-purity, non-carrier-added (n.c.a.) radioisotopes like Lutetium-177. The company is advancing a deep and broad clinical pipeline of targeted radioligand therapies (RLTs) and diagnostics, with its lead candidate, n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11), in Phase 3 for neuroendocrine tumors. ITM operates an integrated model from isotope production to finished drug, positioning it as a key player in the rapidly evolving targeted radiotherapy market.
View full company profile